Quantitative proteomic analysis in HCV-induced HCC reveals sets of proteins with potential significance for racial disparity

Journal of Translational Medicine

Sayed S Daoud¹  David W Koh¹  Xiaoxing Feng¹  Manoj K Bhasin²  Simon T Dillon² 

[1] Department of Pharmaceutical Sciences, Washington State University, Pullman, WA USA;Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, MA USA

关键词: Cancer racial disparity;    Isobaric tags for relative and absolute quantification (iTRAQ);    Tissue proteomics;    Hepatitis C;    Hepatocellular carcinoma;   

Others  :  826164
DOI  :  10.1186/1479-5876-11-239

 received in 2013-07-15, accepted in 2013-09-28,  发布年份 2013

【 摘 要 】

Background

The incidence and mortality of hepatitis C virus (HCV)-induced hepatocellular carcinoma (HCC) is higher in African Americans (AA) than other racial/ethnic groups in the U.S., but the reasons for this disparity are unknown. There is an urgent need for the discovery of novel molecular signatures for HCV disease progression to understand the underlying biological basis for this cancer rate disparity to improve the clinical outcome.

Methods

We performed differential proteomics with isobaric labeling tags for relative and absolute quantitation (iTRAQ) and MS/MS analysis to identify proteins differentially expressed in cirrhotic (CIR) and HCC as compared to normal tissues of Caucasian American (CA) patients. The raw data were analyzed using the ProteinPilot v3.0. Searches were performed against all known sequences populating the Swiss-Prot, Refseq, and TrEMBL databases. Quality control analyses were accomplished using pairwise correlation plots, boxplots, principal component analysis, and unsupervised hierarchical clustering. Supervised analysis was carried out to identify differentially expressed proteins. Candidates were validated in independent cohorts of CA and AA tissues by qRT-PCR or Western blotting.

Results

A total of 238 unique proteins were identified. Of those, around 15% were differentially expressed between normal, CIR & HCC groups. Target validation demonstrates racially distinct alteration in the expression of certain proteins. For example, the mRNA expression levels of transferrin (TF) were 2 and18-fold higher in CIR and HCC in AA as compared to CA. Similarly; the expression of Apolipoprotein A1 (APOA1) was 7-fold higher in HCC of AA. This increase was mirrored in the protein expression levels. Interestingly, the level of hepatocyte nuclear factor4α (HNF4α) protein was down regulated in AA, whereas repression of transcription is seen more in CA compared to AA. These data suggest that racial disparities in HCC could be a consequence of differential dysregulation of HNF4α transcriptional activity.

Conclusion

This study identifies novel molecular signatures in HCV-induced HCC using iTRAQ-based tissue proteomics. The proteins identified will further enhance a molecular explanation to the biochemical mechanism(s) that may play a role in HCC racial disparities.

【 授权许可】

   
2013 Dillon et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]El-Serag HB: Hepatocellular carcinoma: current concepts. N Engl J Med 2011, 365:1118-1127.
• [2]Edlin BR: Perspective: test and treat this silent killer. Nature 2011, 474:S18-S19.
• [3]Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C: Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010, 8:924-933.
• [4]Castello G, Scala S, Palmieri G, Curley SA, Izzo F: HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol 2010, 134:237-250.
• [5]Caldwell S, Park SH: The epidemiology of hepatocellular cancer: From the perspective of public health problem to tumor biology. J Gastroenterol 2009, 44:96-101.
• [6]Mathur AK, Heimbach J, Steffick DE, Sonnenday CJ, Goodrich NP, Merion RM: Donation after cardiac death liver transplantation: predictors of outcome. Am J Transplant 2010, 10:2512-2519.
• [7]Trooskin SB, Navarro VJ, Winn RJ, Axelrod DJ, McNeal AS, Velez M, Herrine SK, Rossi S: Hepatitis C risk assessment, testing and referral for treatment in urban primary care: role of race and ethnicity. World J Gastroenterol 2007, 13:1074-1078.
• [8]Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S: Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol 2010, 44:140-145.
• [9]Artinyan A, Mailey B, Sanchez-Luege N, Khalili J, Sun CL, Bhatia S, Wagman LD, Nissen N, Colquhoun SD, Kim J: Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer 2010, 116:1367-1377.
• [10]Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, El-Kamary SS, Bass EB: Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002, 36:S84-S92.
• [11]Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS: Hepatocellular carcinoma serum markers. Semin Oncol 2012, 2012(39):410-433.
• [12]Paul SB, Gulati MS, Sreenivas V, Madan K, Gupta AK, Mukhopadhyay S, Acharya SK: Evaluating patients with cirrhosis for helpatocellular carcinoma: value of clinical symptomatology, imaging and alpha-fetoprotein. Oncology 2007, 72:117-123.
• [13]Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB: Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol 2012, 10:428-433.
• [14]Nam SW, Park JY, Ramasamy A, Shevade S, Islam A, Long PM, Park CK, Park SE, Kim SY, Lee SH, Park WS, Yoo NJ, Liu ET, Miller LD, Lee JY: Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology 2005, 42:809-818.
• [15]Wang W, Peng JX, Yang JQ, Yang LY: Identification of gene expression profiling in hepatocellular carcinoma using cDNA microarrays. Dig Dis Sci 2009, 54:2729-2735.
• [16]Gehrau RC, Archer KJ, Mas VR, Maluf DG: Molecular profiles of HCV cirrhotic tissues derived a panel of markers with clinical utility for hepatocellular carcinoma surveillance. PLoS One 2012, 7:e40275.
• [17]Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, Giordano TJ, Lannettoni MD, Orringer MB, Hanash SM, Beer DG: Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002, 1:304-313.
• [18]Uto H, Kanmura S, Takami Y, Tsubouchi H: Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proc Natl Acad Sci U S A 2010, 8:70-80.
• [19]Mas VR, Maluf DG, Archer KJ, Yanek K, Bornstein K, Fisher RA: Proteomic analysis of HCV cirrhosis and HCV-induced HCC: Identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation 2009, 87:143-152.
• [20]Nomura F, Sogawa K, Noda K, Seimiya M, Matsushita K, Miyazaki M, Yokosuka O: Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma. Biochem Biophys Res Commun 2012, 421:837-843.
• [21]Diamond DL, Jacobs JM, Paeper B, Proll SC, Gritsenko MA, Carithers RJ Jr, Larson AM, Yeh MM, 2nd Camp DG, Smith RD, Katze MG: Proteomic profiling of human liver biopsies: Hepatitis C virus-induced fibrosis and mitochondrial dysfunction. Hepatology 2007, 46:649-657.
• [22]Diamond DL, Krasnoselsky AL, Burnum KE, Monroe ME, Webb-Robertson B-J, McDermott JE, Yeh MM, Dzib JF, Susnow N, Storm S, Proll SC, Bellisle SE, Purdy DE, Rasmussen AL, Walters KA, Jacobs JM, Gritsenko MA, Camp DG, Bhattacharya R, Perkins JD, Carithers RL Jr, Liou IW, Larson AM, Benecke A, Waters KM, Smith RD, Katze MG: Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus-mediated liver disease posttransplantation. Hepatology 2012, 56:28-38.
• [23]Zhao S, Zun M, Chu Y, Zhu T, Wang Y, Yan L, Xun X, Song J, Shao M: Proteome analysis identifies the role of heat stress in production of progeny HCV in Huh7 cells harboring intact HCV. Intervirology 2008, 51:196-202.
• [24]Sato S, Fukasawa M, Yamakawa Y, Natsume T, Suzuki T, Shoji I, Alzaki H, Miyamura T, Nishijima M: Proteomic profiling and lipid droplet proteins in Hepatoma cell lines expressing hepatitis C virus core protein. J Biochem 2006, 139:921-930.
• [25]McCully JD, Bhasin MK, Daly C, Guerrero MC, Dillon S, Liberman TA, Cowan DB, Mably JD, McGowan FX, Levitsky S: Transcriptomic and proteomic analysis of global ischemia and cardioprotection in the rabbit heart. Physiol Genomics 2009, 38:125-137.
• [26]Glen A, Evans CA, Gan CS, Cross SS, Hamdy FC, Gibbins J, Lippitt J, Eaton CL, Noirel J, Wright PC, Rehman I: Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study. Prostate 2010, 70:1313-1332.
• [27]Shilov IV, Seymour SL, Patel AA, Loboda A, Tang WH, Keating SP, Hunter CL, Nuwaysir LM, Schaeffer DA: The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics 2007, 6:1638-1655.
• [28]Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu VV, Yu Q, LaRose J, Kohn KW, Weinstein JN, Pommier Y: Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: A pharmacogenomic study. Cancer Res 2003, 63:2782-2793.
• [29]Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB: Serum retinol binding, protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
• [30]Petta S, Cammà C, Di Marco V, Alessi N, Barbaria F, Cabibi D, Cabibi D, Caldarella R, Ciminnisi S, Licata A, Massenti MF, Mazzola A, Tarantino G, Marchesini G, Crazi A: Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. Hepatology 2008, 48:28-37.
• [31]Lee EK, Han GY, Park HW, Song YJ, Kim CW: Transgelin promotes migration and invasion of cancer stem cells. J Proteome Res 2010, 9:5108-5117.
• [32]Chen XL, Zhou L, Yang J, Shen FK, Zhao SP, Wang YL: Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS. Mol Med Rep 2010, 3:589-596.
• [33]Mogilenko DA, Dizhe EB, Shavva VS, Lapikov IA, Orlov SV, Lapikov IA, Orlov SV, Perevozchikov AP: Role of the nuclear receptors HNF4α, PPARα, and LXRs in the TNFα-mediated inhibition of human apolipoprotein AI gene expression in HepG2 cells. Biochemistry 2009, 48:11950-11960.
• [34]DeSantis C, Siegel R, Bandi P, Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin 2011, 61:409-418.
• [35]Dimou A, Syrigos KN, Saif MW: Disparities in colorectal cancer in African-Americans vs Whites: before and after diagnosis. World J Gastroenterol 2009, 15:3734-3743.
• [36]Bristow RE, Zahurak ML, Ibeau OA: Racial disparities in ovarian cancer surgical care: a population-based analysis. Gynecol Oncol 2011, 121:364-368.
• [37]Chornokur G, Dalton K, Borysova ME, Kumar NB: Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 2011, 71:985-997.
• [38]Jacobs BL, Montgomery JS, Zhang Y, Skolarus TA, Weizer AZ, Hollenbeck BK: Disparities in bladder cancer. Urol Oncol 2011, 30:81-88.
• [39]Lara-Pezzi E, Serrador JM, Montoya MC, Zamora D, Yáñez-Mó M, Carretero M, Furthmayr H, Sanchez-Madrid F, Lopez-Cabrera M: The hepatitis B virus X protein (HBx) induces a migratory phenotype in a CD44-dependent manner: possible role of HBx in invasion and metastasis. Hepatology 2001, 33:1270-1281.
• [40]Sasaki Y, Yamamura H, Kawakami Y, Yamada T, Hiratsuka M, Kameyama M, Ohigashi H, Ishikawa O, Imaoka S, Ishiguro S, Takahashi K: Expression of smooth muscle calponin in tumor vessels of human hepatocellular carcinoma and its possible association with prognosis. Cancer 2002, 94:1777-1786.
• [41]Leung WK, Ching AK, Wong N: Phosphorylation of caldesmon by PFTAIRE1 kinase promotes actin binding and formation of stress fibers. Mol Cell Biochem 2010, 350:201-206.
• [42]Ai J, Huang H, Lv X, Tang Z, Chen M, Chen T, Duan W, Sun H, Li Q, Tan R, Liu Y, Duan J, Yang Y, Wei Y, Li Y, Zhou Q: FLNA and PGK1 are two potential markers for progression in hepatocellular carcinoma. Cell Physiol Biochem 2011, 27:207-216.
• [43]Mancone C, Steindler C, Santangelo L, Simonte G, Vlassi C, Longo MA, D’Offizi G, Di Giacomo C, Pucillo LP, Amicone L, Tripodi M, Alonzi T: Hepatitis C virus production requires apolipoprotein A-I and affects its association with nascent low-density lipoproteins. Gut 2011, 60:378-386.
• [44]Hu SX, Kyulo NL, Xia VW, Hillebrand DJ, Hu KQ: Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of US patients. J Clin Gastroenterol 2009, 43:758-764.
• [45]Tseng HH, Chang JG, Hwang YH, Yeh KT, Chen YL, Yu HS: Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implication. J Cancer Res Clin Oncol 2009, 135:1413-1420.
• [46]Heim MH: Innate immunity and HCV. J Hepatol 2013, 58:564-574.
• [47]Moriishi K, Mochizuki R, Moriya K, Miyamoto H, Mori Y: Abe T, Murata S, Tanaka K, Miyamura T, Suzuki T, Koike K, Matsuura Y: Critical role of PA29gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. PNAS USA 2007, 104:1661-1666.
• [48]García-Mediavilla MV, Pisonero-Vaquero S, Lima-Cabello E, Benedicto I, Majano PL: Liver X receptor α-mediated regulation of lipogenesis by core and NS5A proteins contribute to HCV-induced liver steatosis and HCV replication. Lab Invest 2012, 92:1191-1202.
• [49]Nguyen H, Sankaran S, Dandekar S: Hepatitis C virus core protein induces expression of genes regulating immune evasion and anti-apoptosis in hepatocytes. Virology 2006, 354:58-68.
• [50]Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW, Baba HA: Activation of the ERK and AKT signaling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008, 48:83-90.
• [51]Lin W, Tsai WL, Shao RX, Wu G, Peng LF, Barlow LL, Chung WJ, Zhang L, Zhao H, Jang JY, Chung RT: Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology 2010, 138:2509-2518.
• [52]Hwang-Verslues WW, Sladek FM: HNF4α - role in drug metabolism and potential drug target? Curr Opin Pharmacol 2010, 10:698-705.
• [53]Gautier-Stein A, Zitoun C, Lalli E, Mithieux G, Rajas F: Transcriptional regulation of the glucose-6-phosphatase gene by cAMP/vasoactive intestinal peptide in the intestine. Role of HNF4alpha, CREM, HNF1alpha, and C/EBPalpha. J Biol Chem 2006, 281:31268-31278.
• [54]Hertz R, Seckbach M, Zakin MM, Bar-Tana J: Transcriptional suppression of the transferrin gene by hypolipidemic peroxisome proliferators. J Biol Chem 1996, 271:218-224.
• [55]Sumi K, Tanaka T, Uchida A, Magoori K, Urashima Y, Ohashi R, Ohguchi H, Okamura M, Kudo H, Daigo K, Maejima T, Kokima N, Sakakibara I, Jiang S, Hasegawa G, Kim I, Osborne TF, Naito M, Gonzalez FJ, Hamakubo T, Kodama T, Sakai J: Cooperative interaction between hepatocyte nuclear factor 4α and GATA transcription factors regulates ATP-binding cassette sterol transporters ABCG5 and ABCG8. Mol Cell Biol 2007, 27:4248-4260.
• [56]Ioannou GN, Dominitz JA, Weiss NS, Heagerty PJ, Kowdley KV: Racial differences in the relationship between hepatitis C infection and iron stores. Hepatology 2003, 37:795-801.
• [57]Samantray J, Zambare S, Seyoum B, Abou-Samra AB: Glucose control and lipid metabolism in African American patients with type 2 diabetes mellitus and chronic hepatitis C viral infection. Endocr Pract 2011, 17:363-368.
• [58]Chellappa K, Jankova L, Schnabl JM, Pan S, Brelivet Y, Fung CL-S, Chan C, Dent OF, Clarke SJ, Robertson GR, Sladek FM: Src tyrosine kinase phosphorylation of nuclear factor HNF4α correlates with isoform-specific loss of HNF4α in human colon cancer. PNAS 2012, 109:2302-2307.
• [59]Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras M, Ilipopulos D: An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular carcinoma. Cell 2011, 147:1233-1247.
• [60]Bonzo JA, Ferry CH, Matsubara T, Kim JH, Gonzalez FJ: Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4α in adult mice. J Biol Chem 2012, 287:7345-7356.